Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegavivint Plus Zanzalintinib in Advanced Hepatocellular Carcinoma
NCT07878689Phase 2Not yet recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Dec 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of tegavivint, zanzalintinib in hepatocellular carcinoma (HCC), sponsored by UT Southwestern Medical Center. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
tegavivintzanzalintinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07878689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07878689.